Literature DB >> 7679650

Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a.

T Kretzschmar1, A Jeromin, C Gietz, W Bautsch, A Klos, J Köhl, G Rechkemmer, D Bitter-Suermann.   

Abstract

The receptor for the inflammatory peptide C3a has scarcely been examined on human cells. This work demonstrates that human tumor-derived basophilic granulocytes express C3a receptors, and presents parts of the hitherto unknown C3a-signal transduction. When incubated with IL-3, these cells specifically liberated histamine on C3a stimulation. Independent from IL-3, 240,000 +/- 100,000 receptors per cell with a Kd of 5.6 +/- 0.9 nM were determined. [Ca2+]i increased from 120 +/- 35 nM to 300 +/- 80 nM after a C3a challenge, as measured by digital imaging fluorescence microscopy, and rested at its basal level in the presence of C3a-desArg, the immediate catabolic product of C3a in vivo. This [Ca2+]i increase could be completely desensitized homologously by C3a as well as inhibited by up to 75% by pertussis toxin. Thus, tumor-derived basophils are suitable for cloning of the human C3a receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679650     DOI: 10.1002/eji.1830230239

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

2.  Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis.

Authors:  Griet A Van Roey; Christopher C Vanison; Jeffanie Wu; Julia H Huang; Lydia A Suh; Roderick G Carter; James E Norton; Stephanie Shintani-Smith; David B Conley; Kevin C Welch; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Kathryn E Hulse; Atsushi Kato; Whitney W Stevens; Robert C Kern; Robert P Schleimer; Bruce K Tan
Journal:  J Allergy Clin Immunol       Date:  2016-12-12       Impact factor: 10.793

3.  Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin.

Authors:  K Kirchhoff; O Weinmann; J Zwirner; G Begemann; O Götze; A Kapp; T Werfel
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

4.  Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies.

Authors:  J Zwirner; O Götze; G Begemann; A Kapp; K Kirchhoff; T Werfel
Journal:  Immunology       Date:  1999-05       Impact factor: 7.397

5.  Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity.

Authors:  I Murray; J Köhl; K Cianflone
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

6.  Human monocyte-derived dendritic cells are chemoattracted to C3a after up-regulation of the C3a receptor with interferons.

Authors:  Ralf Gutzmer; Margarete Lisewski; Jörg Zwirner; Susanne Mommert; Carola Diesel; Miriam Wittmann; Alexander Kapp; Thomas Werfel
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

7.  Nonsense-codon-mediated decay in human hereditary complement C3 deficiency.

Authors:  Edimara S Reis; Victor Nudelman; Lourdes Isaac
Journal:  Immunogenetics       Date:  2003-11-25       Impact factor: 2.846

8.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

9.  The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes.

Authors:  U Martin; D Bock; L Arseniev; M A Tornetta; R S Ames; W Bautsch; J Köhl; A Ganser; A Klos
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

Review 10.  Complement System Part II: Role in Immunity.

Authors:  Nicolas S Merle; Remi Noe; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Front Immunol       Date:  2015-05-26       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.